Ep201: Jeremy Levin on Biotech in the Balance

The biotechnology industry faces an existential crisis of public trust, largely stemming from its perceived alignment with the pharmaceutical sector and a failure to articulate its unique value as a driver of innovation. To regain public support and ensure long-term stability, the industry must adopt a new social contract centered on ten core commitments, including unwavering adherence to scientific truth, patient-centric development, and radical transparency. Current practices, such as short-term quarterly financial reporting and a lack of manufacturing resilience, undermine the sector's ability to serve patients effectively. By treating biotechnology as a strategic national asset—comparable to semiconductors or energy—and fostering long-term capital formation, the industry can secure its future. Failure to act risks ceding global leadership in biomedical innovation to international competitors who have already integrated these strategic principles into their national agendas.